Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28843768

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Oct
First author
Dimopoulos MA

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1288-1290. doi: 10.1016/S1470-2045(17)30613-7.
    note
    Source null
    related pmid
    28843767
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Oct;18(10):e562. doi: 10.1016/S1470-2045(17)30721-0.
    note
    Source null
    related pmid
    28971823
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e1. doi: 10.1016/S1470-2045(17)30859-8.
    note
    Source null
    related pmid
    29304356
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8.
    note
    Source null
    related pmid
    29304357
    relationship
    Comment in

Authors and identifiers

  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Goldschmidt H
    type
    Author
  3. name
    Niesvizky R
    type
    Author
  4. name
    Joshua D
    type
    Author
  5. name
    Chng WJ
    type
    Author
  6. name
    Oriol A
    type
    Author
  7. name
    Orlowski RZ
    type
    Author
  8. name
    Ludwig H
    type
    Author
  9. name
    Facon T
    type
    Author
  10. name
    Hajek R
    type
    Author
  11. name
    Weisel K
    type
    Author
  12. name
    Hungria V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dimopoulos MA
    type
    Author
  2. name
    Goldschmidt H
    type
    Author
  3. name
    Niesvizky R
    type
    Author
  4. name
    Joshua D
    type
    Author
  5. name
    Chng WJ
    type
    Author
  6. name
    Oriol A
    type
    Author
  7. name
    Orlowski RZ
    type
    Author
  8. name
    Ludwig H
    type
    Author
  9. name
    Facon T
    type
    Author
  10. name
    Hajek R
    type
    Author
  11. name
    Weisel K
    type
    Author
  12. name
    Hungria V
    type
    Author
bibliography ids
  1. nci-bib-de4d5ecae2dc154ef55ff51a
book metadata
content sha256
92f708864e47ce5fe2ca6217ce020c73033cd0a31dbd18627cc3f5a64209a98c
document type
citation
dois
  1. 10.1016/S1470-2045(17)30578-8
electronic publication date
display
2017 Aug 23
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28843768
immutable id
pubmed:28843768@92f708864e47ce5fe2ca6217ce020c73033cd0a31dbd18627cc3f5a64209a98c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1327-1337
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1288-1290. doi: 10.1016/S1470-2045(17)30613-7.
    note
    Source null
    related pmid
    28843767
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2017 Oct;18(10):e562. doi: 10.1016/S1470-2045(17)30721-0.
    note
    Source null
    related pmid
    28971823
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e1. doi: 10.1016/S1470-2045(17)30859-8.
    note
    Source null
    related pmid
    29304356
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8.
    note
    Source null
    related pmid
    29304357
    relationship
    Comment in
outcomes validated
false
pmid
28843768
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
8aa1a93b7fe06961216b9def7b08c0bf514df2a5fa41b22a2c6123656a40d080
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28843768/
title
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice